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In Brief
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progression has been correlative. This
study now shows that transgenic
expression of the BRAF pseudogene
induces a malignancy in mice resembling
human diffuse large B cell lymphoma,
establishing its oncogenic function.
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Research over the past decade has suggested
important roles for pseudogenes in physiology and
disease. In vitro experiments demonstrated that
pseudogenes contribute to cell transformation
through several mechanisms. However, in vivo evi-
dence for a causal role of pseudogenes in cancer
development is lacking. Here, we report thatmice en-
gineered to overexpress either the full-length murine
B-Raf pseudogene Braf-rs1 or its pseudo ‘‘CDS’’ or
‘‘30 UTR’’ develop an aggressive malignancy resem-
bling human diffuse large B cell lymphoma. We
show that Braf-rs1 and its human ortholog, BRAFP1,
elicit their oncogenic activity, at least in part, as
competitive endogenousRNAs (ceRNAs) that elevate
BRAF expression and MAPK activation in vitro and
in vivo. Notably, we find that transcriptional or
genomic aberrations of BRAFP1 occur frequently in
multiple human cancers, including B cell lymphomas.
Our engineered mouse models demonstrate the
oncogenic potential of pseudogenes and indicate
that ceRNA-mediated microRNA sequestration may
contribute to the development of cancer.
INTRODUCTION
Over the past few years, remarkable progress has been made in
establishing long non-coding RNAs (lncRNAs) as important reg-
ulators of various biological processes. Given their critical roles,it is not surprising that aberrant expression and/or function of
lncRNAs are implicated in the development of diseases such
as cancer (Gutschner and Diederichs, 2012).
Pseudogenes, a sub-class of lncRNA genes that developed
from protein-coding genes but have lost the ability to produce
proteins, have long been viewed as non-functional genomic
relicts of evolution (Poliseno, 2012). However, the vast majority
of pseudogenes have protein-coding parental counterparts
with which they share high sequence homology, which
enables pseudogenes to participate in posttranscriptional regu-
lation of their parental genes. Mechanisms of parental gene
regulation include the formation of endogenous siRNAs (Tam
et al., 2008; Watanabe et al., 2008), recruitment of regulatory
proteins by pseudogene antisense RNAs to complementary
sites in the parental gene to modulate chromatin remodeling
and transcription (Hawkins and Morris, 2010; Johnsson et al.,
2013), and competition for RNA-binding proteins or the transla-
tion machinery (Bier et al., 2009; Chiefari et al., 2010; Han et al.,
2011).
We recently proposed that the high sequence homology en-
ables pseudogenes to compete with their parental genes for a
shared pool of common microRNAs (miRNAs) (Poliseno et al.,
2010), thus regulating the latter’s expression as competitive
endogenous RNA (ceRNAs) (Salmena et al., 2011). This mecha-
nism is of particular relevance to cancer where pseudogenes are
aberrantly expressed (Kalyana-Sundaram et al., 2012). Specif-
ically, we demonstrated that pseudogenes of the frequently
mutated cancer genes PTEN and KRAS function as ceRNAs
in vitro (Poliseno et al., 2010). Moreover, we and others reported
that mRNAs and non-coding RNAs may serve as ceRNAs that
regulate each other through miRNA-dependent crosstalk
(Cazalla et al., 2010; Cesana et al., 2011; Franco-Zorrilla et al.,Cell 161, 319–332, April 9, 2015 ª2015 Elsevier Inc. 319
2007; Hansen et al., 2013; Karreth et al., 2011; Libri et al., 2012;
Marcinowski et al., 2012; Memczak et al., 2013; Sumazin et al.,
2011; Tay et al., 2011; Wang et al., 2013), suggesting that pseu-
dogenes regulate the expression of their parental genes in the
context of larger networks of protein-coding and non-coding
ceRNAs.
While sufficient data exist to demonstrate pseudogene func-
tions in vitro, in vivo evidence for the regulatory activity of
pseudogenes—either as ceRNAs or by any of the other above-
mentioned mechanisms—is lacking, and their role in disease
progression is correlative. Here, we describe a causal role for
the BRAF pseudogene in the development of cancer.
RESULTS
The BRAF Pseudogene Regulates BRAF in a
Dicer1-Dependent Manner
The BRAF pseudogene (BRAFP1) is overexpressed in various
tumor types (Zou et al., 2009; Kalyana-Sundaram et al., 2012),
suggesting that it may contribute to cancer development. We
have shown that pseudogenes are able to regulate expression
of their parental genes through sequestration of shared miRNAs
(Poliseno et al., 2010), and BRAFP1-mediated elevation of BRAF
may promote MAPK signaling and tumorigenesis. MiRNA pre-
dictions revealed that murine Braf-rs1 (Gm18189) and B-Raf
are targeted by 54 and 114 miRNA families, respectively, 53 of
which they have in common. Similarly, human BRAFP1 and
BRAF are targeted by 60 and 48 miRNA families, respectively,
and share 40 (Figures S1A–S1D, Table S1). Thus, the BRAF
pseudogene may operate as a ceRNA for BRAF in mice and hu-
mans. Indeed, ectopic expression of Braf-rs1 in NIH 3T3 fibro-
blasts and BRAFP1 in human PC9 and HeLa cancer cells
elevated BRAF protein and ERK phosphorylation (Figures 1A
and S1E). Importantly, B-Raf was critical for this effect, as the
Braf-rs1-induced increase in pERKwas negated by genetic dele-
tion of B-Raf in B-Raffl/fl fibroblasts (Figure 1B). Moreover,
expression of the BRAF pseudogene increased proliferation of
NIH 3T3, PC9, and HeLa cells (Figures 1C, 1D, and S1F). Moder-
ate B-Raf overexpression was sufficient to increase pERK
expression, proliferation, and anchorage-independent growth
of NIH 3T3 fibroblasts (Figures S1G–S1I), indicating that Braf-
rs1-mediated elevation of B-Raf may be sufficient for the
observed phenotype.
To test whether the effect of the BRAF pseudogene on BRAF
expression and proliferation rates was dependent on miRNAs,
we utilized cell lines lacking functional Dicer1, a ribonuclease
critical for miRNA biogenesis and whose deficiency results in
drastically reduced levels of mature miRNAs (Cummins et al.,
2006; Ravi et al., 2012). Ectopic expression ofBraf-rs1 increased
expression of B-Raf and pERK and elevated proliferation of
Dicer1-proficient murine sarcoma cells, but not that of isogenic
Dicer1 knockout cells (Figures 1E and 1F). Similarly, overexpres-
sion of BRAFP1 in Dicer1-proficient human HCT116 colon can-
cer cells increased expression of BRAF and pERK and elevated
proliferation, and these effects were abrogated in isogenic
Dicer1 mutant HCT116 cells (Figures 1G and 1H). Thus, the
BRAF pseudogene-induced effects are dependent on BRAF
and Dicer1.320 Cell 161, 319–332, April 9, 2015 ª2015 Elsevier Inc.The BRAF Pseudogene Regulates BRAF as a
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The finding that the BRAF pseudogene mediates its effect
through mature miRNAs suggests that it may function as a
ceRNA. To test this directly, we co-expressed BRAFP1 with a
human BRAF-30 UTR-luciferase reporter in Dicer1-proficient
and -deficient HCT116 cells. BRAFP1 elevated the activity of
the BRAF 30 UTR-luciferase reporter in a Dicer1-dependent
manner (Figure 2A), further supporting the notion that the cross-
talk is mediated by mature miRNAs. To validate this result, we
tested several predicted shared miRNAs in 30 UTR-luciferase re-
porter assays. Three out of ten murine miRNAs (miR-134, miR-
543, and miR-653) significantly repressed Braf-rs1 and B-Raf
luciferase reporters (Figure 2B), suggesting that the crosstalk
may be mediated at least in part by these three miRNAs.
Next, we determined the ability of Braf-rs1 to decoy the dual
targeting miRNAs miR-134, miR-543, and miR-653 from lucif-
erase reporters carrying miRNA response elements (MREs).
Braf-rs1 regulated the expression of the luciferase reporters,
especially at lower miRNA concentrations (Figure 2C). Braf-
rs1-mediated sequestration of the least potent of the three
dual targeting miRNAs, miR-543, had the most robust effect on
luciferase reporter activity (Figure 2C). These data suggest that
both potency and abundance of the miRNAs may be important
determinants for ceRNA crosstalk. In addition, Braf-rs1 was
able to sequester endogenous miR-653, miR-134, and miR-
543 from the respective luciferase-MRE reporters, and mutation
of the MREs in Braf-rs1 abrogated this effect (Figure 2D).
Similarly, four out of nine human miRNAs (miR-30a, miR-182,
miR-876, and miR-590) were able to repress BRAF- and
BRAFP1-luciferase reporters (Figure S2A). miR-30a, miR-182,
and miR-876 were also efficiently sequestered from the respec-
tive MRE-luciferase reporters by BRAFP1, andmutation of these
miRNA-binding sites reduced BRAFP1’s activity as a miRNA
sponge (Figure S2B).
Generation of TRE-BPS Mice
As Braf-rs1 regulates the expression of B-Raf and MAPK
signaling, we sought to investigate whether aberrant Braf-rs1
expression is oncogenic in vivo. To this end, we generated a
transgenic allele containing murine Braf-rs1 under the control
of a doxycycline (Dox)-inducible Tet-response element (TRE)
and targeted it to the collagen A1 locus using Flp recombi-
nase-mediated genomic integration (Beard et al., 2006) (Figures
S2C and S2D). We isolated mouse embryonic fibroblasts (MEFs)
from TRE-Braf-rs1 (henceforth referred to as TRE-BPS) mice to
confirm that expression of the Braf-rs1 allele regulates B-Raf.
Infection of MEFs with a tTA-expressing retrovirus resulted in
6- to 18-fold induction of Braf-rs1 expression (Figures 2E and
S2E), as well as increased levels of B-Raf and pERK (Figure 2F)
and proliferation (Figure 2G), confirming that the transgenic allele
elicits effects similar to ectopic expression of Braf-rs1.
We used TRE-BPSMEFs to analyze the stoichiometry ofB-Raf
and Braf-rs1. First, we determined the absolute number of tran-
scripts by qPCR using plasmids carrying Braf-rs1 and B-Raf as
standards (Figure S2E). In TRE-BPSMEFs infectedwith a control
retrovirus, B-Raf molecules were 13- to 26-fold more abundant
than Braf-rs1, while in tTA-infected cells, the B-Raf:Braf-rs1 ratio
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Figure 1. The BRAF Pseudogene Regulates
BRAF in a Dicer1-Dependent Manner
(A) Western blot demonstrating increased BRAF
and pERK expression upon ectopic BRAF pseu-
dogene expression in mouse (NIH 3T3, left) and
human (PC9, right) cells.
(B) Western blot of B-Raffl/fl fibroblasts over-
expressing Braf-rs1 or control (yellow fluorescent
protein [YFP]) in the presence or absence of
Adeno-Cre infection.
(C) Increased proliferation of NIH 3T3 fibroblasts
upon ectopic Braf-rs1 expression.
(D) Increased proliferation of PC9 cells upon
ectopic BRAFP1 expression.
(E and F) Western blot (E) and proliferation assay
(F) of Dicer1FL/D and Dicer1D/D murine sarcoma
cells overexpressing Braf-rs1.
(G and H) Western blot (G) and proliferation assay
(H) of Dicer1WT and Dicer1Mut human HCT116
colon cancer cells overexpressing BRAFP1.
Error bars represent mean ± SD. *p% 0.05; **p%
0.01; ***p% 0.001. See also Figure S1.
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Figure 2. The BRAF Pseudogene Functions as a miRNA Sponge
(A) BRAF 30 UTR-luciferase reporter assay in Dicer1WT and Dicer1Mut HCT116 cells expressing BRAFP1 or control (YFP).
(B) Luciferase reporter assay using the 30 UTRs of B-Raf and Braf-rs1 to analyze repression by the indicated miRNAmimics. miR141 serves as a negative control.
(C) Braf-rs1 sequesters miRNAs to regulate MRE-Luc reporter activity. HEK293T cells were co-transfected with MRE-Luc reporter constructs, the respective
miRNA mimics, and Braf-rs1-L277 or empty control L277 plasmids. The luciferase activity relative to a Luc reporter without MRE is shown.
(D) Luciferase activity measured in HEK293T cells co-expressing MRE-Luc reporters (Luc-653, Luc-134, or Luc-543) and wild-type or MRE mutant Braf-rs1 or
empty vector.
(E) qPCR showing tTA-induced Braf-rs1 expression in TRE-BPS MEFs.
(F) Western blot for B-Raf and pERK in tTA-infected TRE-BPS MEFs.
(G) Proliferation of TRE-BPS MEF1 shown in (F).
Error bars represent mean ± SD. *p% 0.05; **p% 0.01; ***p% 0.001. See also Figure S2.was between 1.3 and 2.5 (Figure S2E). RNA-sequencing (RNA-
seq) analysis confirmed Braf-rs1 induction and found B-Raf:
Braf-rs1 ratios in a range similar to that determined by qPCR (Fig-322 Cell 161, 319–332, April 9, 2015 ª2015 Elsevier Inc.ure S2F and data not shown). Next, we determined the number of
molecules of miR-653, miR-134, andmiR-543 in TRE-BPSMEFs
by qPCR using standard curves. MiRNA expression was not
significantly affected upon transgene induction (Figure S2G,
Table S2). Mir-653 was expressed at extremely low levels, likely
precluding it from Braf-rs1/B-Raf ceRNA crosstalk in MEFs.
Additional predicted miRNAs that are expressed in MEFs (Table
S2) but were not further validated may also contribute to cross-
talk. Hence, the stoichiometry of B-Raf, transgenic Braf-rs1, and
some dual-targeting miRNAs fits well within the optimal cross-
talk criteria that we have recently established (Ala et al., 2013),
supporting the hypothesis that overexpression of Braf-rs1 in-
creases B-Raf through its ceRNA activity.
Braf-rs1 Causes Diffuse Large B Cell Lymphoma
To induce global overexpression of Braf-rs1 in vivo, TRE-BPS
mice were crossed to CAG-rtTA3 mice (Premsrirut et al., 2011),
and compound mutant animals and single mutant controls
were placed on a Dox-containing diet at 3 weeks of age (Fig-
ure S3A). qPCR analysis after 4 weeks of Dox administration
confirmed Braf-rs1 overexpression in all organs tested (Fig-
ure S3B). Following 4 months of Dox treatment, TRE-BPS;
CAG-rtTA3 mice became moribund and had to be sacrificed
after a median survival of 421 days (Figure 3A), while none of
the single-mutant animals or compound mutants maintained
on a regular diet developed similar symptoms. All moribund
TRE-BPS; CAG-rtTA3 mice presented with splenomegaly (Fig-
ures 3B and 3C) and enlarged lymph nodes (Figure 3K).
Histological analysis revealed large tumor nodules involving
the splenic white pulp (Figures 3D and 3E). Tumors consisted
of large lymphoid cells admixed with numerous plasmablasts
and plasma cells (Figure 3F). The mitotic rate was very high (Fig-
ure 3F), and the proliferation rate was markedly increased
compared to normal white pulp (Figures 3G and S3C).
We determined the immunophenotype of the splenic tumors
by flow cytometry when TRE-BPS; CAG-rtTA3 mice succumbed
to the malignancy. The cell population expressing surface B220
was decreased in spleens (Figure 3H), while Gr-1+/Mac-1+ cells
were slightly increased and CD3+ cells were unchanged (Figures
3I and 3J). Lymph nodes displayedmore B220+ cells, while CD3+
cells were less abundant (Figures 3L and 3M). Similar results
were obtained when calculated as fold change relative to con-
trols (Figures S3D–S3H). By immunohistochemistry, tumor cells
stained positively for CD45R/B220 and IgG (Figures 4A and 4C)
and negatively for CD3 (Figure 4B). Moreover, tumors were
negative for the germinal center marker Bcl6 (Figure 4D) and
strongly positive for Mum1 (Figure 4E), while residual germinal
centers adjacent to the tumors were Bcl6 positive and Mum1
negative (Figures 4D and 4E). The decrease of B220 expression
on the surface of tumor cells reflected themarked plasmacellular
differentiation, as shown by the abundance of IgG+ cells. Overall,
this phenotype was consistent with post-germinal center diffuse
large B cell lymphoma.
We next determined the abundance of Braf-rs1, B-Raf, and
miRNA molecules in spleens after short-term Dox exposure
(10 days) and in lymphomas and control spleens after long-
term Dox exposure. While endogenous Braf-rs1 expression
was between 6- and 115-fold lower than B-Raf, expression of
transgenic Braf-rs1 was comparable to B-Raf (Figures S3I–
S3L). Expression of miR-134, miR-543, and miR-653 was not
affected by Braf-rs1 overexpression (Figures S3M and S3N).Similar to MEFs, miR-653 was expressed at low levels, while
miR-134 and miR-543 were expressed at levels that are
amenable to ceRNA crosstalk (Figures S3M and S3N).
Aggressive Lymphomas Are Transplantable and Depend
on Braf-rs1 Expression
Macroscopic lymphoma nodules were commonly observed in
the kidneys, livers, and lungs of TRE-BPS; CAG-rtTA3 mice (Fig-
ure 4F and data not shown), and histological analysis revealed
microscopic organ infiltration by lymphoma cells in all animals
(Figures 4G–4I). Such tumor cells displayed a CD45R/B220+
and Mum1+ phenotype identical to the cells infiltrating spleens
and lymph nodes (Figures 4J–4O). Additionally, heterozygous
loss of Pten reduced the median survival of TRE-BPS; CAG-
rtTA3 mice to 172 days (data not shown).
To further assess the tumorigenicity of Braf-rs1-induced lym-
phomas, we analyzed their transplantation potential. NSG mice
injected with TRE-BPS; CAG-rtTA3 spleen cells had to be sacri-
ficed 100–150 days after transplantation due to deteriorating
health. Moreover, NSG mice transplanted with TRE-BPS;
CAG-rtTA3; Pten+/ lymphoma cells had to be sacrificed after
80 days (data not shown). NSG recipients exhibited infiltrating
lymphoma cells in spleens, livers, lungs, and kidneys (Figure 5A).
These results suggest that Braf-rs1-induced lymphomas are
transplantable and highly aggressive.
We next determined whether continuous expression of Braf-
rs1 was required for tumor maintenance. TRE-BPS; CAG-rtTA3
receiving aDox-diet weremonitored by palpation andwere taken
off Dox chow once splenomegaly became apparent. Spleen
sizes of these animals were subsequently measured using
high-resolution ultrasound. Notably, enlarged spleens of all
TRE-BPS;CAG-rtTA3mice reduced in size,while spleens of con-
trol mice were unaffected (Figure 5B). Moreover, 40 days after
weaning the mice off Dox chow, the histology (Figures 5C and
5D) andMum1expressionpattern (Figures 5Eand5F) of thewhite
pulp of TRE-BPS; CAG-rtTA3 spleens were comparable to con-
trols, confirming that lymphomas had largely regressed.
Braf-rs1 Regulates B-Raf In Vivo
To determine whether Braf-rs1 functions as a ceRNA for B-Raf
in vivo, we examined Braf-rs1-induced lymphomas for expres-
sion of B-Raf and pERK. Notably, Braf-rs1-induced lymphomas
displayed increased levels of B-Raf and pERK (Figures 5G, 5H,
andS4A) compared toadjacent normalwhitepulp. Thedifference
in B-Raf and pERK levels between tumors and normal white pulp
in the samemouse is likely due to positive selection of B cells that
express the highest levels of Braf-rs1, B-Raf, and pERK.
We next analyzed whether MAPK signaling is critical for the
growth of Braf-rs1-induced lymphomas. To this end, we treated
NSG mice that were transplanted with Braf-rs1-induced
lymphoma cells with the MEK inhibitor GSK1120212. Notably,
treatment with GSK1120212 markedly impaired the ability of
transplanted lymphomas to colonize the livers of NSGmice (Fig-
ure 5I). Moreover, Dox withdrawal reduced B-Raf and pERK
expression in tumors, indicating that increased MAPK activation
is stimulated by continuous Braf-rs1 expression (Figure S4B).
These data suggest that Braf-rs1 elicits its oncogenic effects,
at least in part, through B-Raf and the MAPK pathway.Cell 161, 319–332, April 9, 2015 ª2015 Elsevier Inc. 323
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Figure 3. Braf-rs1 Expression In Vivo Results in a Lymphoid Malignancy
BPS, TRE-BPS; CAG-rtTA3 mice on Dox; control, TRE-BPS, or CAG-rtTA3 mice on Dox here and in all figures.
(A) Survival of BPS and control mice.
(B and C) Size (B) and weight (C) of BPS and control mouse spleens.
(D and E) Photomicrograph of a spleen from a control (D) and BPS mouse (E).
(F) Higher-magnification photomicrograph showing tumor cells in a BPS spleen.White arrowheads denote plasma cells, and black arrowhead highlights amitotic
figure.
(G) Quantification of Ki-67 staining.
(H–J) Flow cytometry-based quantification of splenic B220+ (H), CD3+ (I), and Gr-1+/Mac-1+ (J) populations.
(K) Size of control and BPS mouse lymph nodes.
(L and M) Flow cytometry-based quantification of B220+ (L) and CD3+ (M) populations in lymph nodes.
Error bars represent mean ± SD. See also Figure S3.
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Figure 4. Braf-rs1 Induces Diffuse Large B Cell Lymphoma
(A) CD45R/B220 staining. Higher magnification inset shows staining of large lymphoma cells.
(B) CD3 staining. Higher-magnification inset shows positive staining of reactive T cells.
(C) IgG staining. Arrowheads denote plasma cells.
(D) Bcl6 staining. Lymphoma cells are negative, and residual germinal center is positive.
(E) Mum1 staining. Tumor cells are positive, and residual germinal center is negative.
(F) Photograph of control and BPS kidneys. Arrowheads denote tumor nodules.
(G–I) H&E staining of kidney (G), liver (H), and lung (I) sections from BPS mice.
(J–L) CD45R/B220 immunohistochemistry of kidney (J), liver (K), and lung (L) sections from BPS mice.
(M–O) Mum1 immunohistochemistry of kidney (M), liver (N), and lung (O) sections from BPS mice.
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Figure 5. Lymphomas Are Transplantable, Are Addicted to Braf-rs1 Expression, and Activate the MAPK Pathway
(A) Transplanted lymphoma cells infiltrating the spleen, liver, kidney, and lungs of NSG recipient mice.
(B) Spleen size measurements after Dox withdrawal.
(C–F) H&E staining (C and D) and Mum1 immunohistochemistry (E and F) of BPS and control mouse spleens depicted in (B) after Dox withdrawal.
(G) Immunohistochemical staining for B-Raf of lymphoma and adjacent normal white pulp in BPS spleen.
(H) Immunohistochemical staining for pERK of lymphoma and adjacent normal white pulp in BPS spleen.
(I) Percentage of liver infiltration by TRE-BPS; CAG-rtTA3; Pten+/ lymphoma cells transplanted into NSG mice in response to GSK1120212 treatment. Each
symbol represents a liver section, and each recipient mouse is color coded.
Error bars represent mean ± SD. ***p% 0.001. See also Figure S4.The ‘‘CDS’’ and ‘‘30 UTR’’ of Braf-rs1 Possess Oncogenic
Potential
Based on Braf-rs1’s ability to decoy miRNAs, we reasoned that
shorter fragments of Braf-rs1 may be able to crosstalk with326 Cell 161, 319–332, April 9, 2015 ª2015 Elsevier Inc.B-Raf through a subset of the shared miRNA pool. Such frag-
mentswould elicit similar phenotypes provided that the crosstalk
remains robust. Alternatively, different portions of Braf-rs1
may regulate distinct ceRNA networks and yield distinct,
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Figure 6. Braf-rs1CDS and Braf-rs13
0UTR
Possess Oncogenic ceRNA Activity Similar
to Full-Length Braf-rs1
(A and B)Weights of spleens (A) and inguinal lymph
nodes (B) of the indicated mouse strains after
6 months on Dox.
(C) Survival of TRE-BPS3
0UTR and TRE-BPSCDS
mice.
(D) Table summarizing the penetrance, median
survival, and disease onset of TRE-BPS, TRE-
BPS3
0UTR, and TRE-BPSCDS mice.
(E) H&E staining of Braf-rs13
0UTR-induced lym-
phoma. White arrowheads indicate plasma cells,
and black arrowhead indicates mitotic figure.
(F–J) Immunohistochemical staining of Braf-
rs13
0UTR-induced lymphoma for Ki-67 (F), CD45R/
B220 (G), CD3 (H), Bcl6 (I), and Mum1 (J).
Error bars represent mean ± SD. See also
Figure S5.B-Raf-unrelated phenotypes. To experimentally examine these
possibilities, we generated two additional Dox-inducible mouse
models overexpressing either the ‘‘CDS’’ or the ‘‘30 UTR’’ ofBraf-
rs1 (Figures S2C and S2D). TRE-BPSCDS and TRE-BPS3
0UTR
mice were crossed to CAG-rtTA3 mice and their offspring fed a
Dox-containing diet for 6 months. Remarkably, both TRE-
BPSCDS and TRE-BPS3
0UTR mice displayed enlarged spleens
and lymph nodes similar to full-length TRE-BPS mice (Figures
6A and 6B).Braf-rs13
0UTR overexpression resulted in splenomeg-
aly and reduced survival (Figures 6C and 6D and S5C) similar to
TRE-BPS mice. The histology and immunophenotype of lym-
phomas in TRE-BPS3
0UTR mice were similar to that of full-length
TRE-BPS animals (Figures 6E–6J, S5A, and S5B), indicating
that Braf-rs13
0UTR overexpression elicits a phenotype similar to
full-length Braf-rs1. TRE-BPSCDS mice developed lymphomas
with a reduced penetrance and aggressiveness compared to
mice overexpressing full-lengthBraf-rs1 orBraf-rs13
0UTR (Figures
6C and 6D and data not shown). Similarly, infection of TRE-
BPSCDS and TRE-BPS3
0UTR MEFs with tTA-pMSCV induced
Braf-rs1CDS and Braf-rs13
0UTR expression (Figure S5D), but only
Braf-rs13
0UTR elicited a significant effect on B-Raf expressionCell 161, 319and proliferation, while the Braf-rs1CDS-
induced effects were negligible (Figures
S5D–S5G). Braf-rs1CDS and Braf-rs13
0UTR
may regulate distinct ceRNA networks,
but the finding that the severity of the
phenotype elicited by the three Braf-rs1
variants correlated with their ability to
deregulate B-Raf provides compelling
support to the notion that Braf-rs1 oper-
ates as a proto-oncogenic ceRNA
through B-Raf in B cells.
BRAFP1 Is an Oncogenic ceRNA in
Human Cancer
Overexpression of human BRAFP1 in-
creased BRAF and pERK levels as well
as proliferation of human cells (Figures1A, 1D, 1G, and 1H), suggesting that BRAFP1 may be an onco-
gene in human cancer. To explore this possibility further, we first
determined whether BRAFP1 is expressed in human DLBCL.
Interestingly, BRAFP1 expression was not found in primary hu-
man B cells (Figures 7A and S6A) but was detected in 30% of
human primary DLBCL and 20% of human DLBCL cell lines (Fig-
ures 7A and S6A). Similar observations have been made in the
thyroid, where BRAFP1 was expressed in some tumors, but
not in normal tissue (Zou et al., 2009). Moreover, BRAFP1 was
expressed in melanoma, prostate cancer, and lung cancer cell
lines (Figure S6A).
We next interrogated TheCancer GenomeAtlas’s (TCGA) cBio
Cancer Genomics Portal for genomic abnormalities of the locus
containing BRAFP1. As pseudogene data are not yet included in
TCGA, we focused our analysis on two protein-coding genes
flanking BRAFP1: ZDHHC15 and MAGEE2 (Figure S6B).
Notably, concurrent copy-number gains and amplification of
ZDHHC15 and MAGEE2 were observed in numerous cancer
types (Figure S6B). Importantly, BRAFP1 expression could be
detected in such cancer types (Kalyana-Sundaram et al.,
2012). Thus, both transcriptional mechanisms and genomic–332, April 9, 2015 ª2015 Elsevier Inc. 327
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Figure 7. BRAFP1 in Human Cancer
(A) Percentage of primary human B cells, primary human DLBCL, and human DLBCL cell lines expressing BRAFP1 as determined by qPCR analysis.
(B and C) Positive correlation of BRAFP1 and BRAF expression in human DLBCL primary tumors (B) and cell lines (C).
(D–G) Western blot for BRAF and pERK in OCI-Ly18 (D), H1299 (E), PC9 (F), and OCI-Ly1 (G) cells in response to BRAFP1 silencing.
(H–K) Proliferation of OCI-Ly18 (H), H1299 (I), PC9 (J), and OCI-Ly1 (K) cells in response to BRAFP1 silencing.
(L) Western blot for BRAF and pERK in OCI-Ly1 cells overexpressing BRAFP1.
(legend continued on next page)
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aberrations may lead to abnormal BRAFP1 expression in human
cancer.
Our experiments in human cell lines indicate thatBRAFP1may
operate as a ceRNA to regulate BRAF expression. Accordingly,
analysis of RNA sequencing data revealed that BRAFP1 and
BRAF expression were positively correlated in primary human
DLBCL tumors and DLBCL cell lines (Figure 7B and 7C). We
also analyzed whether the expression of dual-targeting miRNAs
correlates with BRAF and/or BRAFP1 expression. While miR-
590 expression negatively correlated with BRAFP1 levels, miR-
30a, miR-182, and miR-876 showed no correlation (Figure S6C).
Thus, similar to our observations in TRE-BPS MEFs, expression
of BRAFP1 and BRAF may not affect miRNA abundance in
human DLBCL.
To functionally validate the oncogenic function of BRAFP1 in
human cancer, we designed shRNAs to specifically silence
expression of endogenous BRAFP1 (Figure S6H). Knockdown
of BRAFP1 in OCI-Ly18 DLBCL cells and H1299 and PC9 lung
cancer cells reduced the expression of BRAF and pERK (Figures
7D–7F and S6I–S6K). BRAFP1 silencing moderately reduced
BRAF mRNA levels in OCI-Ly18 and PC9 cells, but not in
H1299 cells, suggesting that the mechanism of miRNA-medi-
ated regulation of BRAF varies between cell lines. Importantly,
the BRAFP1 hairpins had no effect on BRAF and pERK expres-
sion in OCI-Ly1 DLBCL cells that do not express endogenous
BRAFP1 (Figure 7G). Moreover, BRAFP1 silencing reduced pro-
liferation of OCI-Ly18, H1299, and PC9 cells, but not of OCI-Ly1
cells (Figures 7H–7K). Remarkably, silencing of endogenous
BRAFP1 elicited a significant effect on BRAF expression in
OCI-Ly18, H1299, and PC9 cells even though it is 15- to
30-fold less abundant than BRAF (Figures S6D and S6E).
Intriguingly, BRAFp1 was turned over significantly faster than
BRAF (Figure S6F), suggesting that the relatively low expression
levels of BRAFP1may be due to its short half-life. We also deter-
mined the abundance ofmiR-30a,miR-182, andmiR-876 in OCI-
Ly18, H1299, and PC9 cells and found that their expression
levels were in the same range as those of BRAFP1 and BRAF
(Figures S6G).
Overexpression of BRAFP1 in three human DLBCL cell
lines lacking endogenous BRAFP1 expression, SU-DHL-4,
Karpas422, and OCI-Ly1 (Figures S6A and S6L), resulted in
elevated BRAF and pERK levels (Figures 7L and S6M). More-
over, BRAFP1 overexpression increased proliferation of all three
DLBCL cell lines (Figures 7M, S6N, and S6O) and resulted in
increased growth of xenotransplanted OCI-Ly1 cells in the
bone marrow of NSG recipients (Figure 7N). These data suggest
that BRAFP1 has oncogenic properties in human cancer.
DISCUSSION
We investigated whether pseudogenes exert critical functions in
the context of a whole organism and whether their perturbation
contributes to the development of disease. We focused on the(M) Proliferation of OCI-Ly1 cells.
(N) Percentage of human CD19+ transplanted OCI-Ly1 cells in bone marrow of N
(O) Model depicting the proposed oncogenic action of the BRAF pseudogene.
Error bars represent mean ± SD. *p% 0.05; **p% 0.01; ***p% 0.001. See alsoBRAF pseudogene, as it exists in humans and mice and is de-
regulated in cancer (Kalyana-Sundaram et al., 2012; Zou et al.,
2009). Our study establishes the BRAF pseudogene as a potent
proto-oncogene that can elicit a phenotype resembling human
diffuse large B cell lymphoma. Remarkably, no additional
engineered mutations were required to drive this phenotype,
and lymphomas completely regressed upon Dox withdrawal,
emphasizing the oncogenic potential of the BRAF pseudogene.
While it is possible that the BRAF pseudogene elicits its effects
through more than one mechanism or pathway, the fact that
both the CDS and the 30 UTR of Braf-rs1 displayed a similar
phenotype to full-length Braf-rs1, albeit with different severity,
supports the notion that Braf-rs1 functions as a ceRNA to regu-
late B-Raf in vivo (Figure 7O). Whether the oncogenic activity of
Braf-rs1 also requires additional ceRNA targets or non-ceRNA-
related mechanisms will be the focus of future studies.
Several groups, including ours, have generated mathematical
models to quantitatively assess the response of a ceRNA
network to perturbations (Ala et al., 2013; Bosia et al., 2013; Fig-
liuzzi et al., 2013). More recently, such models were used in
conjunction with miRNA predictions, RNA sequencing, and
target site occupancy analyses to more accurately characterize
miRNA competition (Bosson et al., 2014; Denzler et al., 2014;
Jens and Rajewsky, 2014). Intriguingly, these studies yielded
disparate conclusions. It was proposed that ceRNA crosstalk
is unlikely to occur upon physiological changes of ceRNA
expression based on these models’ estimates of the number of
additional target sites required to achieve significant expression
changes of other targets (Denzler et al., 2014; Jens and Rajew-
sky, 2014). By contrast, using Argonaute iCLIP and RNA-seq,
Sharp and colleagues determined that a relatively low number
of additional target sites could elicit ceRNA crosstalk when the
number of miRNA molecules and high-affinity target sites
approaches equimolarity (Bosson et al., 2014). Interestingly,
BRAFP1 is several-fold less abundant than BRAF, yet its
silencing significantly diminished BRAF expression levels,
MAPK signaling, and proliferation. BRAF and its pseudogene
harbor high-affinity sites for the murine and human miRNAs
that we validated as potential mediators of the ceRNA crosstalk
(miRs-134, -543, and -653 and miRs-30a, -182, -876, respec-
tively). Notably, the levels of these miRNAs in mouse spleens
and lymphomas as well as human cancer cell lines are amenable
to miRNA competition in accordance with the model proposed
by Bosson et al. Thus, a ceRNA effect of BRAFP1 that is solely
based on miRNA competition may be compatible with this
model.
Importantly, the studies by the groups of Sharp, Stoffel, and
Rajewsky focused on ceRNA regulation that is mediated by a
singlemiRNA. However, ceRNA pairs in general, and gene/pseu-
dogene pairs in particular, share numerous miRNAs. This in-
creases the likelihood of shared miRNAs being present at cross-
talk-favoring levels, and we have shown that ceRNA crosstalk is
enhanced when it is mediated by more miRNAs (Ala et al., 2013).SG recipients.
Figure S6.
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As discussed by Jens and Rajewsky, several factors that may
influence ceRNA crosstalk are neglected in current mathemat-
ical models. For instance, subcellular co-localization of miRNAs
and competing targets may result in local concentrations that
favor ceRNA crosstalk. In addition, target degradation may
trap miRNAs in P bodies or other sites of RNA decay, thus ampli-
fying the ceRNA regulation by removing miRNAs from the avail-
able pool. Intriguingly, BRAFP1 is degraded significantly faster
than BRAF (Figure S6F); however, whether this influences the
ceRNA activity of BRAFP1 remains to be determined. Future
improvements to both quantitative measurements and mathe-
matical models will undoubtedly provide a better understanding
of the molecular conditions required for ceRNA crosstalk. How-
ever, it should be noted that ceRNA crosstalk can be predicted
solely based on the MRE overlap of transcripts (Chiu et al.,
2014; Karreth et al., 2011; Sumazin et al., 2011; Tay et al.,
2011), suggesting that miRNA competition is indeed the central
component of ceRNA crosstalk.
Human hematopoietic malignancies are associated with
‘‘overdosage’’ of the X chromosome, which harbors the BRAF
pseudogene locus. This can occur through XIST deletion and X
chromosome duplication in women with myeloid cancers, and
extra X chromosomes have been noted in a variety of hemato-
poietic cancers of both sexes (Dewald et al., 1989; Dierlamm
et al., 1995; Heinonen et al., 1999; Paulsson et al., 2010;
Rack et al., 1994; Yamamoto et al., 2002), including DLBCL
(Bea et al., 2005; Monni et al., 1996; Morin et al., 2013). Our anal-
ysis revealed that a variety of human cancers harbor copy-num-
ber gains and amplifications of the locus containingBRAFP1. It is
therefore tempting to speculate that increased X dosage and the
potentially associated overexpression of BRAFP1 contribute to
the development and/or progression of cancer cases harboring
more than one active copy of the X chromosome. Moreover,
elevated expression of BRAFP1 has been observed in cancers
other than DLBCL (Kalyana-Sundaram et al., 2012; Zou et al.,
2009), and transcriptional deregulation may thus be another
means to deregulate BRAFP1 expression. Whether BRAFP1
has oncogenic potential in other organs such as the thyroid re-
mains to be determined through the use of tissue-specific over-
expression of the BRAF pseudogene.
Interestingly, several observations suggest that the BRAF
pseudogenes evolved independently in mice and humans.
First, they reside in non-syngeneic locations—on chromosome
10 in mice and on the X chromosome in humans. Second,
the 30 UTR of the BRAF gene is not conserved between mice
and humans; importantly, however, the BRAF pseudogene
30 UTRs display high sequence homology to their parental
counterparts in the respective species. Third, murine Braf-rs1
arose from an alternative B-Raf splice form that is specific to
mice (Karreth et al., 2009). The likely parallel yet converging
evolution of BRAFP1 and Braf-rs1 and the fact that the
gene-pseudogene crosstalk is mediated by different miRNAs
in the two species suggest that their functions may be
conserved. Indeed, the frequent BRAFP1 copy-number gains
and transcriptional activation of BRAFP1 in human cancers
as well as our silencing and overexpression experiments indi-
cate that our findings in the mouse are of relevance to human
disease.330 Cell 161, 319–332, April 9, 2015 ª2015 Elsevier Inc.It was recently proposed that human BRAFP1 encodes a pep-
tide with the ability to activate the MAPK pathway (Zou et al.,
2009). We neither detected any peptide translation by themouse
or human BRAF pseudogenes nor could we detect robust asso-
ciation of Braf-rs1 with actively translating ribosomes (data not
shown). These findings suggest that Braf-rs1 is not translated
into an oncogenic peptide but, rather, exerts its function as a
RNA transcript. This is further supported by the finding that
TRE-BPS3
0UTR mice display amore severe phenotype compared
to TRE-BPSCDS mice, which suggests that the effects of Braf-rs1
on B-Raf are primarily mediated through its 30 UTR. The BRAFP1
ORF predicted by Zou et al., however, localizes to the CDS
portion of the pseudogene.
Pseudogenes were considered genomic junk for decades, but
their retention during evolution argues that they may possess
important functions and that their deregulation could contribute
to the development of disease. Indeed, several lines of evidence
have associated pseudogenes with cellular transformation (Poli-
seno, 2012). Our study shows that aberrant expression of a
pseudogene causes cancer, thus vastly expanding the number
of genes that may be involved in this disease. Moreover, our
work emphasizes the functional importance of the non-coding
dimension of the transcriptome and should stimulate further
studies of the role of pseudogenes in the development of
disease.
EXPERIMENTAL PROCEDURES
Flow Cytometry
Mice were euthanized and single-cell suspensions from spleens and lymph
nodes were prepared by passing organs through 100 mm cell strainers in 2%
FBS/PBS, centrifuged and re-suspended in 1–2 ml ACK red cell lysis buffer
(GIBCO). Red blood cells were lysed on ice for 1 min. Cell suspensions were
then washed in 2% FBS/PBS, centrifuged and re-suspended in 1 ml 2%
FBS/PBS. For hematopoietic lineage analysis, we usedmonoclonal antibodies
specific for the following: CD3e-PE (145-2C11), B220-FITC (RA3-6B2), Gr-1-
APC (RB6-8C5), and CD11b-PE/Cy7 (M1/70). All antibodies were from
eBioscience. To assess cell viability, cells were incubated with DAPI prior to
FACS analysis. All staining mixtures were analyzed on a BD LSR II flow cytom-
eter (Becton Dickinson). Resulting profiles were further processed and
analyzed using the FlowJo 8.7 software. For fold change quantifications,
both mutant and control cell populations were normalized to the average of
the controls. At least five mice from different litters were used for all flow
cytometry experiments.
Tissue Fixation, H&E, and IHC
Tissues were fixed in 4% paraformaldehyde overnight and embedded in
paraffin according to standard procedures. 5 mm sections were either stained
with hematoxylin & eosin or with the following antibodies: CD45R/B220
(ab64100, Abcam), CD3 (ab5690, Abcam), Ki-67 (RM-9106-S1, Thermo
Scientific), IgG (BA2000, Vector), BRAF (sc-9002, Santa Cruz), pERK (4373,
Cell Signaling), Bcl-6 (5650, Cell Signaling), and Mum1 (sc-6059, Santa
Cruz). Organs from at least five mice from different litters were used for all
stainings.
Cell Culture
HCT116 andHeLawere fromATCC, Dicer mutant HCT116 cells were provided
by B. Vogelstein, and DicerFL/D and DicerD/D mouse sarcoma cells were pro-
vided by P. Sharp and were cultured in DMEM containing 10% FCS and
2 mM L-glutamine. PC9, H1299, H441, and H2009 (all provided by L. Cantley),
OCI-Ly8, OCI-Ly3, RCK8, and Val were grown in RPMI-1640 containing 10%
FCS and 2 mM L-glutamine. SU-DHL-4, SU-DHL-8, Karpas422, OCI-Ly7,
Toledo, OCI-Ly1, and OCI-Ly18 cells were grown as previously described
(Chapuy et al., 2013). Cells were regularly tested with MycoAlert (Lonza) to
ascertain that cells were not infected with mycoplasma.
Plasmids, Transfection, and Virus Infection
Human BRAFP1 was cloned into pLenti-CMV-GFP-Puro (Addgene 25873)
and pCDNA3, and mouse Braf-rs1 was cloned into pCCL.sin.PPT.hPGK.
GFP.Wpre (L277, L. Naldini) or pCDNA3-neo. pMSCV-tTA (Addgene #18783)
was used to induce Braf-rs1 expression in TRE-BPS MEFs. Lipofectamine
2000 was used for plasmid transfection. Lentivirus or retrovirus was produced
in HEK293T LentiX cells (Clontech) co-transfected with VSVG, pMDL, and Rev
or Eco helper plasmids, respectively. Viral supernatants were filtered and cells
infected in the presence of 5 mg/ml polybrene.
Proliferation Assays
For proliferation assays, 23 104 cells were plated in four 12-well plates in trip-
licates. Every day, one plate was fixed with 4% paraformaldehyde and stained
with Crystal Violet. The dye was extracted with 10% acetic acid and its absor-
bance determined at OD595. For suspension cells, 13 10
4 cells were plated in
triplicates in round-bottom 96-well plates and counted every day for 5 days.
Luciferase Assays
HCT116 cells were transfected with 150 ng of psiCHECK2 vector or
psiCHECK2-humanBRAF 30 UTR and 1 mg human BRAFP1 constructs using
Lipofectamine 2000. To validate miRNA targeting, 30 UTRs of murine and hu-
man gene and pseudogene were cloned into psiCHECK2. 5 3 104 HEK293T
cells were transfected in 48-well plates with 20 ng of psiCHECK2 reporter
and 100 nM miRNA mimic (QIAGEN). To test the ceRNA activity of the BRAF
pseudogenes, 5 3 104 HEK293T cells were transfected in 48-well plates
with 20 ng of psiCHECK2 reporter and 250 ng of murine Braf-rs1-L277 vector
or human BRFAP1-pCDNA3 and 1–2 nM miRNA mimic. In all transfections,
firefly luciferase activity was used as a normalization control for transfection
efficiency. 48 hr after transfection, luciferase activities weremeasured consec-
utively with the dual luciferase reporter system (Promega).
Western Blot
Cells were lysed in RIPA buffer containing HALT protease and phosphatase in-
hibitors (Sigma). 20 mg total protein were separated on 4%–12%Bis-Tris acryl-
amide NuPAGE gradient gels in MOPS SDS buffer (Invitrogen). The following
antibodies were used: HSP90 (610419, BD), BRAF (sc5284, Santa Cruz),
pERK (9101, Cell Signaling), and tERK (9102, Cell Signaling). Secondary
HRP-tagged antibodies and ECL detection reagent were from Amersham.
Image J software was used for quantification.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
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